CA2311742A1 - 6-amino-9-benzyl-8-hydroxypurine derivatives - Google Patents

6-amino-9-benzyl-8-hydroxypurine derivatives Download PDF

Info

Publication number
CA2311742A1
CA2311742A1 CA002311742A CA2311742A CA2311742A1 CA 2311742 A1 CA2311742 A1 CA 2311742A1 CA 002311742 A CA002311742 A CA 002311742A CA 2311742 A CA2311742 A CA 2311742A CA 2311742 A1 CA2311742 A1 CA 2311742A1
Authority
CA
Canada
Prior art keywords
optionally substituted
hydroxypurine
benzyl
derivatives
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002311742A
Other languages
French (fr)
Other versions
CA2311742C (en
Inventor
Ayumu Kurimoto
Tetsuhiro Ogino
Hajime Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2311742A1 publication Critical patent/CA2311742A1/en
Application granted granted Critical
Publication of CA2311742C publication Critical patent/CA2311742C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Abstract

Heterocyclic compounds represented by general formula (I) or pharmaceutically acceptable salts thereof, and interferon inducers, antiviral agents, anticancer agents and remedies for immunologic diseases containing the same as the active ingredient wherein X represents sulfur, oxygen or -NR3-, or R3 and R1 may form together an optionally substituted heterocycle via nitrogen; R1 represents optionally substituted alkyl, optionally substituted aryl or an optionally substituted heterocycle; and R2 represents hydrogen, halogeno, etc.
CA002311742A 1997-11-28 1998-11-26 6-amino-9-benzyl-8-hydroxypurine derivatives Expired - Fee Related CA2311742C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP34742297 1997-11-28
JP9/347422 1997-11-28
JP9/367451 1997-12-11
JP36745197 1997-12-11
JP36744997 1997-12-17
JP9/367449 1997-12-17
PCT/JP1998/005318 WO1999028321A1 (en) 1997-11-28 1998-11-26 Novel heterocyclic compounds

Publications (2)

Publication Number Publication Date
CA2311742A1 true CA2311742A1 (en) 1999-06-10
CA2311742C CA2311742C (en) 2009-06-16

Family

ID=27341247

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002311742A Expired - Fee Related CA2311742C (en) 1997-11-28 1998-11-26 6-amino-9-benzyl-8-hydroxypurine derivatives

Country Status (12)

Country Link
US (1) US6329381B1 (en)
EP (1) EP1035123B1 (en)
JP (1) JP4375901B2 (en)
KR (1) KR100613634B1 (en)
AT (1) ATE247654T1 (en)
AU (1) AU732361B2 (en)
CA (1) CA2311742C (en)
DE (1) DE69817393T2 (en)
ES (1) ES2205573T3 (en)
NZ (1) NZ504800A (en)
TW (1) TWI222973B (en)
WO (1) WO1999028321A1 (en)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ27399A3 (en) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
SE9903544D0 (en) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (en) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
SE0101322D0 (en) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
ES2314042T3 (en) * 2001-04-17 2009-03-16 Dainippon Sumitomo Pharma Co., Ltd. NEW DERIVATIVES OF ADENINA.
SE0102716D0 (en) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
EP1427445A4 (en) * 2001-08-30 2006-09-06 3M Innovative Properties Co Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
PT1719511E (en) * 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AU2002357295A1 (en) 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CA2495570C (en) 2002-08-15 2012-12-04 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
MXPA05003193A (en) * 2002-09-27 2005-06-08 Sumitomo Pharma Novel adenine compound and use thereof.
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004091500A2 (en) * 2003-04-10 2004-10-28 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005011629A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
JP2007501252A (en) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー Formulation containing immune response modifier
CA2535117A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
AU2004268616B2 (en) 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2536578A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
AP2006003542A0 (en) 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2543685A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
RU2409576C2 (en) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Systems containing imidazole ring with substitutes, and methods of obtaining said systems
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
CA2549606C (en) * 2003-12-22 2015-10-06 K.U. Leuven Research & Development Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
NZ549903A (en) 2004-03-26 2010-04-30 Astrazeneca Ab 9-substituted 8-oxoadenine compound
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-oxoadenine compound
EP1740587A4 (en) * 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Selective antagonists of a-2a- adenosine receptors
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
ES2560449T3 (en) 2004-05-28 2016-02-19 Oryxe A mixture for transdermal administration of low and high molecular weight compounds
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006023381A1 (en) * 2004-08-16 2006-03-02 Taigen Biotechnology Pyrimidinone compounds
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
DK2561872T3 (en) 2004-12-17 2014-12-08 Anadys Pharmaceuticals Inc 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
EP1841765B1 (en) * 2004-12-21 2009-03-25 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compound and method of antiviral treatment
JP5313502B2 (en) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds
US8461174B2 (en) 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
MX2007013780A (en) 2005-05-04 2008-02-05 Pfizer Ltd 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c.
EP1931352B1 (en) * 2005-08-22 2016-04-13 The Regents of The University of California Tlr agonists
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
JPWO2007034917A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
JPWO2007034882A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20090192153A1 (en) * 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007034817A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
WO2007034916A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
CA2630463C (en) 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
EP1955708A4 (en) 2005-11-24 2013-02-06 Dainippon Sumitomo Pharma Co Novel memory ctl induction potentiator
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US7709448B2 (en) 2006-06-22 2010-05-04 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
US7754720B2 (en) * 2006-07-07 2010-07-13 Gilead Sciences, Inc. Pyridazine compound and use thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
BRPI0714831A2 (en) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc compound, pharmaceutical composition and methods of modulating cytokine immune activities in a patient, treating hepatitis virus infection and in a patient, and proliferation-related disorder in a mammal in need thereof
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
CA2677733A1 (en) 2007-02-07 2008-09-25 The Regents Of The University Of California Conjugates of synthetic tlr agonists and uses therefor
EP2132209B8 (en) * 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
WO2008114006A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
PL2155743T3 (en) 2007-05-08 2013-01-31 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
UY31531A1 (en) 2007-12-17 2009-08-03 SALTS DERIVED FROM 8-OXOADENINE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY AS TOLL TYPE RECEIVER MODULATORS (TLR)
WO2009091031A1 (en) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. Method for producing adenine compound
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
PL2364314T3 (en) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulators of toll-like receptors
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (en) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 Toll-like receptor modulators and treatment of diseases
ES2538839T3 (en) 2009-04-28 2015-06-24 Zenyaku Kogyo Kabushikikaisha Purine derivative and antitumor agent that uses it
EA201101650A1 (en) 2009-05-21 2012-07-30 Астразенека Аб NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EA022699B1 (en) * 2009-05-27 2016-02-29 Селекта Байосайенсиз, Инк. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
EA201592264A1 (en) 2009-08-26 2016-08-31 Селекта Байосайенсиз, Инк. COMPOSITIONS WHICH INDUCE T-CELL HELPER EFFECT
NO2491035T3 (en) 2009-10-22 2018-01-27
JP2013512859A (en) 2009-12-03 2013-04-18 大日本住友製薬株式会社 Imidazoquinoline acting through a toll-like receptor (TLR)
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
CN107029223A (en) 2010-05-26 2017-08-11 西莱克塔生物科技公司 Synthesize nano-carrier combined vaccine
IT1401281B1 (en) 2010-08-05 2013-07-18 Univ Firenze PREPARATION OF CONJUGATES BETWEEN ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE IN SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF ALLERGIC DISEASES.
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP5978225B2 (en) 2010-12-16 2016-08-24 大日本住友製薬株式会社 Imidazo [4,5-c] quinolin-1-yl derivatives useful for therapy
ES2627433T3 (en) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives
US20120231023A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
AU2012238564A1 (en) 2011-04-08 2013-09-26 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
EA028254B1 (en) 2011-05-18 2017-10-31 Янссен Сайенсиз Айрлэнд Юси Quinazoline derivatives for the treatment of viral infections and further diseases
CN103582496B (en) 2011-06-03 2016-05-11 3M创新有限公司 There is the Heterobifunctional connection base of polyethylene glycol segment and the immune response modifier conjugate of being made by it
EP2718292B1 (en) 2011-06-03 2018-03-14 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
KR20140050698A (en) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
PL2776439T3 (en) 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
AU2013218072B2 (en) 2012-02-08 2017-08-31 Janssen Sciences Ireland Uc Piperidino-pyrimidine derivatives for the treatment of viral infections
SG11201407115XA (en) 2012-05-18 2014-12-30 Sumitomo Dainippon Pharma Co Ltd Carboxylic acid compounds
LT2872515T (en) 2012-07-13 2016-10-10 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
KR102216479B1 (en) 2012-08-10 2021-02-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP2712866A1 (en) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
PL2906563T3 (en) 2012-10-10 2018-10-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
JP6297055B2 (en) 2012-11-16 2018-03-20 ヤンセン・サイエンシズ・アイルランド・ユーシー Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PT2941233T (en) 2013-01-07 2020-11-13 Univ Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
CN105188744A (en) 2013-03-14 2015-12-23 哈佛大学的校长及成员们 Nanoparticle-based compositions
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
UA117586C2 (en) 2013-05-24 2018-08-27 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Pyridone derivatives for the treatment of viral infections and further diseases
SI3030563T1 (en) 2013-06-27 2017-12-29 Janssen Sciences Ireland Uc Pyrrolo (3,2-d) pyrimidine derivatives for the treatment of viral infections and other diseases
DK3404031T3 (en) 2013-07-30 2020-12-14 Janssen Sciences Ireland Unlimited Co THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EP3160453A1 (en) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CN112898308A (en) 2014-08-15 2021-06-04 正大天晴药业集团股份有限公司 Pyrrolopyrimidines as TLR7 agonists
EP3194401B1 (en) 2014-09-16 2020-10-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CA2969587A1 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
US20180110784A1 (en) * 2015-04-09 2018-04-26 The Regents Of The University Of California Synthetic tlr4 and tlr7 ligands to prevent, inhibit or treat liver disease
WO2017048807A1 (en) 2015-09-17 2017-03-23 Jrx Biotechnology, Inc. Approaches for improving skin hydration or moisturization
US10597397B2 (en) 2015-09-29 2020-03-24 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
TWI558709B (en) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
CN107043380A (en) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 A kind of maleate of TLR7 activators, its crystal formation C, crystal formation D, crystal formation E, preparation method and purposes
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
IL293475A (en) * 2016-08-29 2022-08-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
KR102450287B1 (en) 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Pyrimidine prodrugs for treatment of viral infections and additional diseases
ES2906439T3 (en) 2016-12-05 2022-04-18 Apros Therapeutics Inc Pyrimidine Compounds Containing Acid Groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
EP3603619A4 (en) 2017-03-29 2020-12-09 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
US10494370B2 (en) * 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
CN116115765A (en) 2017-12-21 2023-05-16 住友制药株式会社 Combination comprising TLR7 agonists
BR112020016859A2 (en) 2018-02-28 2020-12-29 Pfizer Inc. IL-15 VARIANTS AND USES OF THE SAME
TW201945003A (en) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-diaminoquinazoline derivatives and medical uses thereof
KR20230146098A (en) 2018-05-23 2023-10-18 화이자 인코포레이티드 Antibodies specific for gucy2c and uses thereof
WO2019224715A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
US10857153B2 (en) 2018-06-04 2020-12-08 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
EP4182346A1 (en) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutic antibodies and their uses
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8511222D0 (en) 1985-05-02 1985-06-12 Wellcome Found Antiviral compounds
JPH08165292A (en) * 1993-10-07 1996-06-25 Techno Res Kk Adenine derivative,its production and application
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
KR100518903B1 (en) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Immune response modifier compounds for treatment of the th2 mediated and related diseases

Also Published As

Publication number Publication date
NZ504800A (en) 2001-10-26
AU732361B2 (en) 2001-04-26
EP1035123A4 (en) 2001-12-12
ES2205573T3 (en) 2004-05-01
EP1035123B1 (en) 2003-08-20
TWI222973B (en) 2004-11-01
AU1260299A (en) 1999-06-16
ATE247654T1 (en) 2003-09-15
WO1999028321A1 (en) 1999-06-10
EP1035123A1 (en) 2000-09-13
KR20010032571A (en) 2001-04-25
WO1999028321A9 (en) 1999-09-10
CA2311742C (en) 2009-06-16
KR100613634B1 (en) 2006-08-18
JP4375901B2 (en) 2009-12-02
DE69817393D1 (en) 2003-09-25
DE69817393T2 (en) 2004-06-17
US6329381B1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
CA2311742A1 (en) 6-amino-9-benzyl-8-hydroxypurine derivatives
AU6052594A (en) New heterocyclic compounds
EP0976748A4 (en) Pyrrolidine derivatives having phospholipase a2 inhibitory activity
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
HU9500240D0 (en) New prolin-amide derivatives and pharmaceutical compositions containing them as active component
ES2095833T3 (en) DERIVATIVES OF BENZODIAZEPINAS.
IL96882A0 (en) Uracil derivatives and pesticides containing the same as active ingredient
FI890689A0 (en) 3-ALKENYL-1-AZABICYCLO- / 3.2.0 / -HEPT-2-EN-2-CARBOXYLSYRAFOERENINGAR.
EP0522173A4 (en) 4-desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable salt thereof
DE69021855T2 (en) Quinazoline derivatives and their preparation.
EP0878196A4 (en) Kainic acid neuronotoxicity inhibitors and pyridothiazine derivatives
HU9203849D0 (en) Thiazole derivatives
FI895139A0 (en) PYRROLIDINDERIVAT.
AU7506591A (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
AU7962000A (en) Us0027324for eating disorders
AU5264593A (en) Imidazole derivatives
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20121126